Enabling the synthesis of homogeneous or Janus hairy nanoparticles through surface photoactivation.

Nanoscale

Dipartimento di Scienza Applicata e Tecnologia Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129, Torino, Italy.

Published: August 2018

Nanoparticles (NPs) homogeneously covered with polymer chains or with chains of two different polymers segregated in distinct domains ("Janus" particles) possess remarkable features. Their unique colloidal properties can be finely tuned by the grafted polymers while the characteristics of the nano-core remain unaffected. Herein, a simple and robust photochemical approach is reported to synthesize, from 50 nm cores, homogeneous and Janus "hairy" nanoparticles with hydrophilic and amphiphilic properties, respectively. This is achieved by using a surface-anchored bis(acyl)phosphane oxide photoinitiator which allows a spatially controlled surface-initiated photopolymerization at room temperature. Homogeneous and Janus hairy nanoparticles dispersed in water have very different interaction behaviours which are directly visualized by in situ liquid cell transmission electron microscopy and confirmed by small angle X-ray scattering from a statistically relevant number of particles.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8nr04239jDOI Listing

Publication Analysis

Top Keywords

homogeneous janus
12
janus hairy
8
hairy nanoparticles
8
enabling synthesis
4
synthesis homogeneous
4
nanoparticles
4
nanoparticles surface
4
surface photoactivation
4
photoactivation nanoparticles
4
nanoparticles nps
4

Similar Publications

Acute lung injury i.e. ALI and its serious form acute respiratory distress syndrome (ARDS) are incurable medical conditions associated with significant global mortality and morbidity.

View Article and Find Full Text PDF

Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment.

J Phys Chem B

December 2024

Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China.

Inhibition of virus replication and inflammatory response is important for the treatment of severe COVID-19 patients. RNA-dependent RNA polymerase (RdRp) is indispensable for SARS-CoV-2 replication, and Janus kinase (JAK) 1 inhibitors exert immunosuppressive effects. RdRp/JAK1 dual-target drugs are expected to ameliorate the severity of the COVID-19 disease.

View Article and Find Full Text PDF

Transdermal drug delivery systems are a promising option for the treatment of rheumatoid arthritis (RA) because they can lower systemic adverse effects of immunosuppressants. Janus kinase (JAK) inhibitors were found to be effective for the treatment of RA by inhibiting the JAK-STAT pathway and preventing autoimmune joint destruction. The aim of this study is to deliver tofacitinib (a JAK 1 and 3 inhibitor) through mannose-decorated transferosomes (MDTs) directly to inflamed joints.

View Article and Find Full Text PDF

JAK inhibitors: an evidence-based choice of the most appropriate molecule.

Front Pharmacol

October 2024

Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Janus kinase inhibitors (JAKis) represent a fundamental therapeutic tool for the treatment of patients with immune-mediated inflammatory diseases. Although JAKis are often considered a homogeneous class of drugs whose members are thought to be largely interchangeable, there are significant differences in their efficacy and safety profiles. This narrative review analyzes the pharmacokinetic and pharmacodynamic differences among JAKIs, highlighting their clinical relevance based on the most recent available evidence.

View Article and Find Full Text PDF

Background: Sarcopenia is a muscle disease characterized by reduction of muscle strength and muscle mass. In RA, 25.9 to 43.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!